The Dynamic Monitoring of Cerebrospinal Fluid ctDNA

Summary

Focusing on advanced EGFR mutation in NSCLC patients with leptomeningeal metastasis, vormetinib combined with OMMAYA lateral ventricle chemotherapy (pemetrexed) was used to dynamically monitor ctDNA in cerebrospinal fluid (CSF), analyze the ctDNA gene mutation profile of CSF in different patients, and explore the relationship between ctDNA and efficacy and prognosis.

Timeline

Start

2022-09-29

Primary completion

2024-07-31

Completion

2024-12-31

Drugs

Indications